About the Company
We do not have any company description for Aura Biosciences, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Aura Biosciences, Inc.
Aura Biosciences, Inc. (NASDAQ:AURA) Shares Purchased by Wells Fargo ...
Aura Biosciences, Inc. has a 52 week low of $4.84 and a 52 week high of $12.38. Aura Biosciences (NASDAQ:AURA – Get Free Report) last released its earnings results on Monday, March 24th.
Aura Biosciences Inc (AURA) Receives a Buy from Scotiabank
Based on Aura Biosciences Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.34 million. In comparison, last year the company had ...
Chiesi Ventures, Inc. Cuts Stake in Aura Biosciences Inc (AURA)
Fintel reports that Chiesi Ventures, Inc. has filed a 13G/A form with the SEC disclosing ownership of 1,218,803 shares of Aura Biosciences Inc (AURA). This represents 3.3% of the company.
Aura Biosciences Reports Q2 Results and $75M Financing
Aura Biosciences Inc ( ($AURA) ) just unveiled an announcement. On August 13, 2025, Aura Biosciences reported its second-quarter financial results ...
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc ...
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Aura Biosciences Inc, with a price target of $21.00. The company’s shares closed last Wednesday at $7.70.
Aura Biosciences, Inc. (AURA) Latest Press Releases & Corporate News ...
Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc ...
Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed ...
On May 9, 2024, Aura Biosciences Inc (NASDAQ:AURA), a trailblazer in the field of precision immunotherapies for solid tumors, disclosed its financial outcomes for the first quarter ending March 31 ...
Aura Biosciences, Inc.: Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 ...
Aura Biosciences Reports Fourth Quarter and Full Year ... - Morningstar
BOSTON, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve ...
Aura Biosciences Announces Proposed Public Offering of Common Stock
Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the launch of an ...
Aura Biosciences, Inc.: Aura Biosciences Reports First Quarter 2025 ...
AURA BIOSCIENCES INC WKN: A3C6D1|ISIN: US05153U1079|Ticker-Symbol: NASDAQ 30.07.25 | 21:56 6,560US-Dollar 0,00 % 0,000 Branche Biotechnologie Aktienmarkt NASDAQ Biotech 1-Jahres-Chart 5-Tage-Chart ...
Similar Companies
Loading the latest forecasts...